• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ContextLogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    3/28/25 4:30:07 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $LOGC alert in real time by email
    8-K
    false00018222500001822250logc:ClassCommonStock00001ParValueMember2025-03-252025-03-2500018222502025-03-252025-03-250001822250logc:PreferredStockPurchaseRightsMember2025-03-252025-03-25

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 25, 2025

     

     

    ContextLogic Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39775

    27-2930953

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2648 International Blvd., Ste 115

     

    Oakland, California

     

    94601

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (415) 965-8476

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value

     

    LOGC

     

    Nasdaq Global Select Market

    Preferred Stock Purchase Rights

     

    N/A

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On March 25, 2025, ContextLogic Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff believes the Company is a “public shell,” as that term is defined by Nasdaq under Nasdaq Listing Rule 5101, and therefore subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company disagrees with the Staff’s conclusion and plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least pending the hearing and the issuance of the Panel’s formal decision thereafter.

    At the hearing, the Company plans to present a comprehensive overview of its business and, more specifically, the Company’s efforts to maximize the value of its assets, including opportunities to invest in or acquire one or more operating businesses that provide opportunities for appreciation in value, and to request the continued listing of its securities on Nasdaq. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing on Nasdaq.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ContextLogic Inc.

     

     

     

     

    Date:

    March 28, 2025

    By:

    /s/ Rishi Bajaj

     

     

     

    Rishi Bajaj
    Chief Executive Officer
    Principal Executive Officer

     


    Get the next $LOGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LOGC

    DatePrice TargetRatingAnalyst
    2/3/2022Outperform → Market Perform
    William Blair
    2/2/2022$16.00 → $6.00Hold
    Chardan Capital
    12/23/2021$20.00 → $16.00Buy
    Chardan Capital
    11/17/2021$24.00 → $8.00Overweight
    Barclays
    11/16/2021$17.00 → $16.00Market Outperform
    JMP Securities
    More analyst ratings

    $LOGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Leadership Updates

    Live Leadership Updates

    See more
    • ContextLogic Announces Up to $150 Million Strategic Investment by BC Partners

      Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L

      2/25/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

      LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update

      3/4/22 4:05:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

      LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi

      5/19/21 7:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Financials

    Live finance-specific insights

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    SEC Filings

    See more
    • SEC Form 10-Q filed by ContextLogic Inc.

      10-Q - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:30:19 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:05:15 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by ContextLogic Inc.

      SCHEDULE 13G/A - ContextLogic Inc. (0001822250) (Subject)

      4/18/25 3:58:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LogicBio Therapeutics downgraded by William Blair

      William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform

      2/3/22 4:38:49 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously

      2/2/22 2:52:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously

      12/23/21 8:24:38 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ContextLogic Inc.

      SC 13G/A - ContextLogic Inc. (0001822250) (Subject)

      7/8/24 4:32:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13G/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/14/23 1:47:10 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13D/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/10/23 4:40:05 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bajaj Rishi converted options into 55,856 shares and covered exercise/tax liability with 24,722 shares, increasing direct ownership by 156% to 51,134 units (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      5/8/25 4:10:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Heinberg Marshall converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:49 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Farlekas Michael converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:13 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary